RE:RE:RE:Golden..Revenue is less, EBITDA is less, EPS is less, current contract value is less...everything is less that what medipharm is currently at.
Medipharm team is much stronger than Valens (just look at the management, compliance, legal, etc).
If you've got an actual reason I'd love to read it.